| CONCEPT AND ISSUE |
|
| Year : 2021 | Volume
: 22
| Issue : 2 | Page : 123-126 |
|
|
Mucormycosis in COVID-19 patients: A review
Khina Sharma1, Jyoti2, Ramandeep Kaur1
1 Tutor, College of nursing Government Medical College and Hospital, Chandigarh, India
2 Principal, College of nursing Government Medical College and Hospital, Chandigarh, India
Correspondence Address:
Mrs. Khina Sharma
Government Medical College and Hospital, Chandigarh
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ijcn.ijcn_87_21
|
|
|
Mucormycosis is a rare but invasive, fungal infection mainly found in immunocompromised patients, which occurs due to the fungi mucormycetes. It is a rapidly occurring fungal infection with a high mortality rate. Although rare, the cases of mucormycosis have been raised abnormally in COVID-19 patients in India during second wave, in which a severe rise in COVID-19 cases was reported. Many states of India have already declared it as an epidemic, and the sad part is that the medication to treat it is running low. Mucormycosis has been reported in COVID-19-positive patients at any time after COVID-19 infection, either during hospitalisation or several days to weeks after discharge.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
